Ovarian Cancer Clinical Trial

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

Summary

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Advanced solid tumor
Measurable disease, per RECIST v1.1
Eastern Cooperative Oncology Group (ECOG) performance status 0-1
Adequate organ function

Exclusion Criteria:

Has not recovered [recovery is defined as NCI CTCAE, version 5.0, grade ≤1] from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements
Received prior chemotherapeutic, investigational, or other therapies for the treatment of cancer within 14 days with small molecule and within 28 days with biologic before the first dose of TORL-1-23
Progressive or symptomatic brain metastases
Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection
History of significant cardiac disease
History of myelodysplastic syndrome (MDS) or AML
History of another cancer within 3 years before Day 1 of study treatment, with the exception of basal or squamous cell carcinoma of the skin that has been definitively treated. A history of other malignancies with a low risk of recurrence, including appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate cancer with a Gleason score less than or equal to 6, are also not excluded
If female, is pregnant or breastfeeding

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

70

Study ID:

NCT05103683

Recruitment Status:

Recruiting

Sponsor:

TORL Biotherapeutics, LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

UCLA - JCCC Clinical Research Unit
Los Angeles California, 90095, United States More Info
Gottfried Konecny, MD
Contact
310-794-4955
Gottfired Konecny, MD
Principal Investigator
University of Minnesota
Minneapolis Minnesota, 55455, United States More Info
Boris Winterhoff, MD, PhD
Contact
612-624-8003
Boris Winterhoff, MD, PhD
Principal Investigator
Mayo Clinic in Rochester
Rochester Minnesota, 55905, United States More Info
Andrea Wahner Hendrickson, MD
Contact
855-776-0015
Andrea Wahner Hendrickson, MD
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 1

Estimated Enrollment:

70

Study ID:

NCT05103683

Recruitment Status:

Recruiting

Sponsor:


TORL Biotherapeutics, LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.